Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Geron CorporationGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
- Hagens Berman Sobol Shapiro LLPCAPR 10-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 DeadlineHagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application...
- IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.
- Eli Lilly and CompanyU.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerCompanies: Eli Lilly and CompanyInluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free...
- NAVER D2SFNAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMedImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia NAVER D2SF...
- Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities LawsLowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD)
- Faruqi & Faruqi LLPUNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot UlcersLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
- XORTX Therapeutics Inc.XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market OpportunityInvestigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026
- Corcept Therapeutics IncorporatedCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)REDWOOD CITY, Calif., September 18, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined w
- Theralase Technologies Inc.Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial StatementsTheralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)Toronto, Ontario--(September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and...